137 related articles for article (PubMed ID: 29947047)
1. CXCL13 produced by macrophages due to Fli1 deficiency may contribute to the development of tissue fibrosis, vasculopathy and immune activation in systemic sclerosis.
Taniguchi T; Miyagawa T; Toyama S; Yamashita T; Nakamura K; Saigusa R; Ichimura Y; Takahashi T; Toyama T; Yoshizaki A; Sato S; Asano Y
Exp Dermatol; 2018 Sep; 27(9):1030-1037. PubMed ID: 29947047
[TBL] [Abstract][Full Text] [Related]
2. Fli1 Downregulation in Scleroderma Myeloid Cells Has Profibrotic and Proinflammatory Effects.
Bujor AM; El Adili F; Parvez A; Marden G; Trojanowska M
Front Immunol; 2020; 11():800. PubMed ID: 32508810
[TBL] [Abstract][Full Text] [Related]
3. Disparate Interferon Signaling and Shared Aberrant Basaloid Cells in Single-Cell Profiling of Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease.
Valenzi E; Tabib T; Papazoglou A; Sembrat J; Trejo Bittar HE; Rojas M; Lafyatis R
Front Immunol; 2021; 12():595811. PubMed ID: 33859634
[TBL] [Abstract][Full Text] [Related]
4. Nintedanib downregulates the profibrotic M2 phenotype in cultured monocyte-derived macrophages obtained from systemic sclerosis patients affected by interstitial lung disease.
Soldano S; Smith V; Montagna P; Gotelli E; Campitiello R; Pizzorni C; Paolino S; Sulli A; Cere A; Cutolo M
Arthritis Res Ther; 2024 Mar; 26(1):74. PubMed ID: 38509595
[TBL] [Abstract][Full Text] [Related]
5. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin.
Kubo M; Czuwara-Ladykowska J; Moussa O; Markiewicz M; Smith E; Silver RM; Jablonska S; Blaszczyk M; Watson DK; Trojanowska M
Am J Pathol; 2003 Aug; 163(2):571-81. PubMed ID: 12875977
[TBL] [Abstract][Full Text] [Related]
6. Early systemic sclerosis: short-term disease evolution and factors predicting the development of new manifestations of organ involvement.
Valentini G; Vettori S; Cuomo G; Iudici M; D'Abrosca V; Capocotta D; Del Genio G; Santoriello C; Cozzolino D
Arthritis Res Ther; 2012 Aug; 14(4):R188. PubMed ID: 22901779
[TBL] [Abstract][Full Text] [Related]
7. Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction.
Guiot J; Njock MS; André B; Gester F; Henket M; de Seny D; Moermans C; Malaise MG; Louis R
Sci Rep; 2021 May; 11(1):10882. PubMed ID: 34035374
[TBL] [Abstract][Full Text] [Related]
8. Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease.
Meier C; Freiburghaus K; Bovet C; Schniering J; Allanore Y; Distler O; Nakas C; Maurer B
Sci Rep; 2020 Dec; 10(1):21912. PubMed ID: 33318574
[TBL] [Abstract][Full Text] [Related]
9. Dysregulation of TNF-induced protein 3 and CCAAT/enhancer-binding protein β in alveolar macrophages: Implications for systemic sclerosis-associated interstitial lung disease.
Hua X; Hongbing R; Juan X; Jizan L; Beibei Y
Int J Rheum Dis; 2024 May; 27(5):e15174. PubMed ID: 38720423
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic Regulation of Profibrotic Macrophages in Systemic Sclerosis-Associated Interstitial Lung Disease.
Papazoglou A; Huang M; Bulik M; Lafyatis A; Tabib T; Morse C; Sembrat J; Rojas M; Valenzi E; Lafyatis R
Arthritis Rheumatol; 2022 Dec; 74(12):2003-2014. PubMed ID: 35849803
[TBL] [Abstract][Full Text] [Related]
11. Elevated Circulatory Levels of Microparticles Are Associated to Lung Fibrosis and Vasculopathy During Systemic Sclerosis.
Leleu D; Levionnois E; Laurent P; Lazaro E; Richez C; Duffau P; Blanco P; Sisirak V; Contin-Bordes C; Truchetet ME
Front Immunol; 2020; 11():532177. PubMed ID: 33193304
[TBL] [Abstract][Full Text] [Related]
12. Synergistic Role of Endothelial ERG and FLI1 in Mediating Pulmonary Vascular Homeostasis.
Looney AP; Han R; Stawski L; Marden G; Iwamoto M; Trojanowska M
Am J Respir Cell Mol Biol; 2017 Jul; 57(1):121-131. PubMed ID: 28248553
[TBL] [Abstract][Full Text] [Related]
13. The role of the oncostatin M/OSM receptor β axis in activating dermal microvascular endothelial cells in systemic sclerosis.
Marden G; Wan Q; Wilks J; Nevin K; Feeney M; Wisniacki N; Trojanowski M; Bujor A; Stawski L; Trojanowska M
Arthritis Res Ther; 2020 Jul; 22(1):179. PubMed ID: 32736577
[TBL] [Abstract][Full Text] [Related]
14. The Pathogenesis of Systemic Sclerosis: The Origin of Fibrosis and Interlink with Vasculopathy and Autoimmunity.
Ko J; Noviani M; Chellamuthu VR; Albani S; Low AHL
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762589
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of AGGF1: Potential association with cutaneous and cardiopulmonary involvements in systemic sclerosis.
Takahashi T; Takahashi T; Ikawa T; Terui H; Takahashi T; Segawa Y; Sumida H; Yoshizaki A; Sato S; Asano Y
J Dermatol; 2024 Apr; ():. PubMed ID: 38619119
[TBL] [Abstract][Full Text] [Related]
16. Serum amyloid A is a marker for pulmonary involvement in systemic sclerosis.
Lakota K; Carns M; Podlusky S; Mrak-Poljsak K; Hinchcliff M; Lee J; Tomsic M; Sodin-Semrl S; Varga J
PLoS One; 2015; 10(1):e0110820. PubMed ID: 25629975
[TBL] [Abstract][Full Text] [Related]
17. Single cell analysis in systemic sclerosis - A systematic review.
Fukasawa T; Yoshizaki-Ogawa A; Enomoto A; Yamashita T; Miyagawa K; Sato S; Yoshizaki A
Immunol Med; 2024 May; ():1-12. PubMed ID: 38818750
[TBL] [Abstract][Full Text] [Related]
18. Association Between DNA Damage Response, Fibrosis and Type I Interferon Signature in Systemic Sclerosis.
Vlachogiannis NI; Pappa M; Ntouros PA; Nezos A; Mavragani CP; Souliotis VL; Sfikakis PP
Front Immunol; 2020; 11():582401. PubMed ID: 33123169
[TBL] [Abstract][Full Text] [Related]
19. Systemic Sclerosis and Atherosclerosis: Potential Cellular Biomarkers and Mechanisms.
Gerasimova EV; Shayakhmetova RU; Gerasimova DA; Popkova TV; Ananyeva LP
Front Biosci (Schol Ed); 2023 Dec; 15(4):16. PubMed ID: 38163957
[TBL] [Abstract][Full Text] [Related]
20. CD32 (FcγRIIB) expression is low on CD21
Kourkouni E; Tsiogkas SG; Mavropoulos A; Simopoulou T; Katsiari CG; Bogdanos DP; Sakkas LI
Clin Immunol; 2024 May; 262():110195. PubMed ID: 38494058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
